Get the Stockscreener App
4.83
1.83%
-0.09
After Hours:
4.83
Precision Biosciences Inc stock is traded at $4.83, with a volume of 27,941.
It is down -1.83% in the last 24 hours and down -14.36% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.92
Open:
$4.93
24h Volume:
27,941
Relative Volume:
0.21
Market Cap:
$53.56M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-7.3182
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+5.46%
1M Performance:
-14.36%
6M Performance:
-33.74%
1Y Performance:
-62.32%
1-Day Range:
$4.72
$4.97
1-Week Range:
$4.63
$5.10
52-Week Range:
$3.61
$13.32
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.83 | 50.78M | 52.29M | -73.52M | -100.45M | -0.66 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences Reports First Quarter 2025 Financial Resul - GuruFocus
DTIL Reports Strong Start to 2025 with Clinical Progress | DTIL Stock News - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | DTIL Stock News - GuruFocus
Precision Biosciences Q1 Income From Operations USD -22.112 Million - marketscreener.com
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Accelerates PBGENE-DMD Program for DMD - TipRanks
Precision BioSciences Accelerates Development of PBGENE-DMD With - GuruFocus
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - BioSpace
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 | DTIL Stock News - GuruFocus
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - GuruFocus
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | DTIL Stock News - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 29, 2025 - BioSpace
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Precision BioSciences Strengthens Gene Editing Team with Strategic RSU Awards to New Hires - Stock Titan
Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace
Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia
Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus
Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com
Precision BioSciences, Inc. Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - marketscreener.com
SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brown Melinda | Director |
Mar 26 '25 |
Buy |
4.75 |
1,839 |
8,735 |
9,057 |
| Germano Geno J | Director |
Mar 25 '25 |
Buy |
5.30 |
3,250 |
17,225 |
11,057 |
| Amoroso Michael | President and CEO |
Mar 24 '25 |
Sale |
5.56 |
964 |
5,360 |
109,540 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):